DB 1311
Alternative Names: BNT-324; DB-1311Latest Information Update: 12 Aug 2024
At a glance
- Originator Duality Biologics
- Class Antibodies; Antineoplastics; Drug conjugates; Immunotoxins
- Mechanism of Action DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 31 Jul 2024 DB 1311 receives Orphan Drug status for Squamous cell cancer (Late-stage disease, Metastatic disease) in USA
- 24 Jun 2024 DB 1311 receives Fast Track Designation for Prostate cancer (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater, Hormone refractory) in USA
- 05 Sep 2023 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater, Monotherapy) in USA (IV)